August 11, 2023
Some decent reporting on compounded semaglutide
Yesterday STAT News published a Q&A piece on semaglutide compounding (subscription may be required), calling out the FDA’s recent announcement of reported adverse events:
Just how many adverse event reports were received? Not many. In fact, there were no more than 30 reports sent to the agency from August 2021 through May 2023, according to an FDA spoksperson. In the scheme of things, this is a tiny number of adverse event reports given the exploding popularity of these two drugs.
The story also calls out King & Spaulding – the serially losing law firm in state-law-based lawsuits against compounders – and its representation of Novo Nordisk in suits filed last month against four compounding pharmacies for compounding semaglutide in shortage.
